2023 VB100 Mini Forum – Assisted Reproductive Technology Special Session in Shanghai
In recent years, national policies and public demand have provided strong impetus to the assisted reproductive technology (ART) sector. Companies from traditional medicine, gene sequencing, and digital technology sectors have increasingly entered this field. However, challenges such as payment bottlenecks, success rates, and breakthroughs in R&D innovation still need to be addressed. To this end, VCBeat, VB100, VCBeat Research Institute, and Legend Capital, in collaboration with Bosihui, held the 2023 VB100 Mini Forum – Assisted Reproductive Technology Special Session in Shanghai on March 1. The event brought together leading industry partners to discuss future innovation trends, focusing on hot topics and cutting-edge technologies of concern to the sector.
This forum will invite founders and senior executives from multiple companies in the assisted reproductive technology (ART) sector, including Jiabao Renhe, Weituo Biotechnology, Aivifu, Yunxinsheng, Danlu Capital, Chuangrui Investment, and Hua Ai Boyue, as well as experts from investment institutions. Focusing on industry frontiers, participants will engage in in-depth discussions on topics such as improving success rates through gene sequencing, new directions in drug development, innovations in laboratory automation, whole-process service innovation, and implementation pathways for payment models, working together to create opportunities for win-win cooperation.
Event details are as follows. You are cordially invited to attend!
① Scan the QR code below to apply for a free ticket
② Conference Attendance/Partnership Inquiries: Ms. Liu 19954050801, Ms. Wang 17774983530
Wednesday, March 1, 2023 (Afternoon)
Building 30, Baijiatong Park, No. 388 Shengrong Road, Pudong New Area, Shanghai
VCBeat
VCBeat, founded in 2014, is China’s leading research and media platform for the healthcare industry. It is a third-party industrial service provider in the field of medical innovation, recognized by the National Health Commission, the National Healthcare Security Administration, and the United Front Work Department of the CPC Central Committee. Boasting China’s largest database of healthcare innovation and venture capital resources, VCBeat provides high-quality services to enterprises, government bodies, industrial parks, and investment institutions, including media communication, industry research, brand events, as well as facilitation of investment, financing, and industrial resource matchmaking.
VB100
VB100 is a business unit under Eggshell Technology, dedicated to serving governments, industrial parks, and large corporations. By organizing a diverse range of activities—including summits, competitions, forums, roadshows, seminars, and launch events—VB100 connects governments and large corporations with innovative enterprises, fostering industrial resource collaboration and driving industrial upgrading. Since its establishment, VB100 has expanded its footprint to over 30 cities, including Beijing, Tianjin, Shanghai, Hangzhou, Wuxi, Shaoxing, Nanjing, Ningbo, Suzhou, Shenzhen, Guangzhou, Zhuhai, Wuhan, Zhengzhou, Xi’an, Chengdu, and Chongqing, having hosted more than 300 events and conferences to date.
VCBeat
VCBeat Research Institute has consistently focused on innovation within the healthcare industry, driven by a dual-engine strategy. It is committed to empowering corporate executives, investment decision-makers, and policymakers with data technology capabilities and in-depth industry research expertise, thereby optimizing decision-making outcomes, accelerating industrial development, and serving as an industry accelerator. With seven years of accumulated resources in the healthcare sector, VCBeat maintains the world’s largest database of medical innovation enterprises, housing approximately 70,000 innovative companies, and has established deep connections with over 20,000 enterprises and institutions.